Asbestos Information Legal Mesothelioma Clinical: July 2008

Thursday, July 31, 2008

Fwd: First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval (PR Newswire via Yahoo! Finance)

---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:44 AM
Subject: First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval (PR Newswire via Yahoo! Finance)
To: collegeschoolloan@gmail.com

Rosetta Genomics, Ltd. announces today that the first molecular test based on Rosetta Genomics' proprietary microRNA technology, developed and validated by Columbia University Medical Center , has been approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program.

Tue, 22 Jul 2008 12:30:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=121v42nh9/*http%3A//biz.yahoo.com/prnews/080722/3704767en_public.html?.v=1
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: LegalView Informs Mesothelioma Blog Readers of a Predicted Increase in Female Mesothelioma Victims (PRWeb via Yahoo! News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Mon, Jul 21, 2008 at 5:59 PM
Subject: LegalView Informs Mesothelioma Blog Readers of a Predicted Increase in Female Mesothelioma Victims (PRWeb via Yahoo! News)
To: collegeschoolloan@gmail.com

LegalView updated readers to an alarming prediction by researchers who said the number of female mesothelioma victims may increase within the next few years. Researchers said that asbestos in hair dryers that were previously unregulated may be the cause.

Mon, 21 Jul 2008 07:01:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=122408t3b/*http%3A//news.yahoo.com/s/prweb/20080721/bs_prweb/prweb1127814_1
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Mesothelioma Victims Center The 100% Help Center For Asbestos Related Cancer (PRWeb)

---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Mon, Jul 21, 2008 at 5:59 PM
Subject: Mesothelioma Victims Center The 100% Help Center For Asbestos Related Cancer (PRWeb)
To: collegeschoolloan@gmail.com

According to Americas Watchdog, "if a mesothelioma victim, or the loved one of a mesothelioma victim wants free advice, or help on what to do after a diagnosis of Mesothelioma, we are the absolute best place in the world to call. Not only will we assist in finding the best law firm, but we will help you with everything else". Mesothelioma victims or loved ones of US mesothelioma can call the ...

Mon, 21 Jul 2008 10:15:02 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=11qv6mkv4/*http%3A//www.prweb.com/releases/2008/07/prweb1122994.htm
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc. (PR Newswire via Yahoo! Finance)

---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:44 AM
Subject: Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc. (PR Newswire via Yahoo! Finance)
To: collegeschoolloan@gmail.com

Rosetta Genomics Ltd. , a leader in the development of microRNA-based diagnostics and therapeutics, announced today that it has successfully completed the acquisition of Parkway Clinical Laboratories Inc. , a privately-held company owning a CLIA-certified lab located in Bensalem, Pennsylvania, for an aggregate purchase price of $2,900,000, consisting of $1,900,000 in cash and $1,000,000 of ...

Thu, 24 Jul 2008 07:00:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=1210gb1ks/*http%3A//biz.yahoo.com/prnews/080724/3706800en_public.html?.v=1
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: First Cancer Diagnostic Test Based On Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval (Medical News Today)

---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:44 AM
Subject: First Cancer Diagnostic Test Based On Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval (Medical News Today)
To: collegeschoolloan@gmail.com

Rosetta Genomics, Ltd. (NASDQ: ROSG) announces that the first molecular test based on Rosetta Genomics' proprietary microRNA technology, developed and validated by Columbia University Medical Center (CUMC), has been approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program.

Wed, 23 Jul 2008 11:12:47 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=11n7kj7a4/*http%3A//www.medicalnewstoday.com/articles/115853.php
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients (PRWeb)

---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Tue, Jul 29, 2008 at 7:48 AM
Subject: LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients (PRWeb)
To: collegeschoolloan@gmail.com

LegalView reported a breakthrough test on its mesothelioma blog, which will allow early detection of mesothelioma cancer. Up to this point, the number one reason mesothelioma cancer kills a patient so quickly is due to the fact that it is often misdiagnosed. (PRWeb Jul 29, 2008) Read the full story at http://www.prweb.com/releases/2008/07/prweb1150494.htm

Tue, 29 Jul 2008 08:30:12 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=11q0kanc7/*http%3A//www.prweb.com/releases/2008/07/prweb1150494.htm
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Tuesday, July 29, 2008

Fwd: A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Tue, Jul 29, 2008 at 7:41 AM
Subject: A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin.
To: mesothelioma77@gmail.com

[1]Cancer Chemother Pharmacol. 2008 Jul 25;
Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH

PURPOSE: A pharmacologic analysis of intracavitary doxorubicin in the treatment of patients with intracavitary cancer dissemination was performed to further evaluate the possible benefits of this treatment modality. METHODS: Twenty appendiceal malignancy patients with peritoneal carcinomatosis (PC), three appendiceal malignancy patients with direct extension into the pleural cavity, 20 patients with peritoneal mesothelioma and one patient with pleural mesothelioma were available for pharmacologic monitoring. After intraperitoneal or intrapleural administration of doxorubicin, plasma and peritoneal fluid samples were obtained at 15, 30, 45, 60 and 90 min in all patients. After intrapleural administration, plasma and pleural fluid samples were collected at similar intervals. Tumor and normal tissues were obtained when available. Doxorubicin concentrations were determined by high-performance liquid chromatography (HPLC). RESULTS: Intraperitoneal doxorubicin showed a prolonged retention in the peritoneal cavity. Doxorubicin concentrations in tumor tissue were consistently elevated above intraperitoneal concentrations from 30 through 90 min. For appendiceal malignancy, the concentrations of doxorubicin were significantly higher in minimally aggressive mucinous tumors. Pleural chemotherapy solutions retained doxorubicin to a greater extent than peritoneal fluid. CONCLUSIONS: Doxorubicin shows characteristics favorable for intracavitary administration with sequestration of doxorubicin in cancer nodules.

___
Source: http://www.hubmed.org/display.cgi?uids=18654746
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients (PRWeb via Yahoo! News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jul 29, 2008 at 7:42 AM
Subject: LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients (PRWeb via Yahoo! News)
To: mesothelioma77@gmail.com

LegalView reported a breakthrough test on its mesothelioma blog, which will allow early detection of mesothelioma cancer. Up to this point, the number one reason mesothelioma cancer kills a patient so quickly is due to the fact that it is often misdiagnosed.

Tue, 29 Jul 2008 07:01:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=1222do92e/*http%3A//news.yahoo.com/s/prweb/20080729/bs_prweb/prweb1150494_2
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Veterans With Asbestos-Related Breathing Diseases May Be Entitled To Compensation From The Federal Government, Canada (Medical News Today)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jul 29, 2008 at 7:42 AM
Subject: Veterans With Asbestos-Related Breathing Diseases May Be Entitled To Compensation From The Federal Government, Canada (Medical News Today)
To: mesothelioma77@gmail.com

The Lung Association recommends that navy veterans who worked on ships or shipyards during the Second World War and up until the 1970s to see their doctor for an examination. These veterans may have been exposed to asbestos and may have an asbestos-related breathing disease as a result.

Mon, 28 Jul 2008 12:10:57 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=11np9kguq/*http%3A//www.medicalnewstoday.com/articles/116350.php
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Mesothelioma Victims Center Is The Most Comprehensive Service In The US (PRWeb)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jul 29, 2008 at 7:42 AM
Subject: Mesothelioma Victims Center Is The Most Comprehensive Service In The US (PRWeb)
To: mesothelioma77@gmail.com

Mesothelioma is a lethal form of cancer caused by exposure to asbestos. According to Americas Watchdog, "when mesothelioma happened to a close family member, we did not know where to begin & we are the largest private consumer group in the US. So we have created a safety net for US mesothelioma victims, and their families or loved ones. There is nothing even close to the free services we offer ...

Mon, 28 Jul 2008 10:41:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=11qgtbp4k/*http%3A//www.prweb.com/releases/2008/07/prweb1147704.htm
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Mesothelioma Victims Center Is The Most Comprehensive Service In The US (PRWeb via Yahoo! News)

Fwd: Eden's polluted legacy (The Burlington Free Press)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jul 29, 2008 at 7:42 AM
Subject: Eden's polluted legacy (The Burlington Free Press)
To: mesothelioma77@gmail.com

Waste piles at asbestos mine erode, bury wetlands | Related: EPA begins cleanup | On the Web: EPA on Asbestos

Tue, 29 Jul 2008 08:17:59 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12q7nt0pc/*http%3A//www.burlingtonfreepress.com/apps/pbcs.dll/article?AID=/20080729/NEWS01/80728027
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Tue, Jul 29, 2008 at 7:42 AM
Subject: Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer.
To: mesothelioma77@gmail.com

[1]Ann Oncol. 2008 Jul 24;
Wan C, Meng Q, Yang Z, Tu X, Feng C, Tang X, Zhang C

BACKGROUND: European Organization for Research and Treatment quality of life (QOL) questionnaire (QLQ-C30) has been used frequently and many language versions have been developed, including the simplified Chinese version. It is important to study psychometric properties of the simplified Chinese version from the clinical standpoint. PATIENTS AND METHODS: The simplified Chinese version of the QLQ-C30 was used in a longitudinal study of 600 patients with five types of cancer: lung, breast, head and neck, colorectal, and stomach. The psychometric properties of the scale were evaluated by indicators of validity and reliability coefficients such as Cronbach's alpha and Pearson's correlation coefficient r, standardized response mean (SRM), correlational analysis, t-tests, and structural equation models. RESULTS: Correlation and structural equation model analyses confirmed good construct validity with root mean square error of approximation 0.054, standardized root mean square residual 0.037, non-normed fit index 0.972, and comparative fit index 0.980. The alpha coefficients for all domains are >0.7 except for cognitive functioning (0.49). The test-retest reliability coefficients for most domains are >0.80 except for appetite loss (0.77) and diarrhea (0.75). The QOL score changes after treatments were of statistical significance with higher or moderate SRM in most domains. CONCLUSION: The simplified Chinese version of QLQ-C30 has good validity, reliability, and responsiveness and can be used to measure QOL for Chinese cancer patients.

___
Source: http://www.hubmed.org/display.cgi?uids=18653703
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Monday, July 28, 2008

Fwd: Breast cancer in young families: a qualitative interview study of fathers and their role and communication with their children following the diagnosis of maternal breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 14, 2008 at 4:55 AM
Subject: Breast cancer in young families: a qualitative interview study of fathers and their role and communication with their children following the diagnosis of maternal breast cancer.
To: mesothelioma77@gmail.com

[1]Psychooncology. 2008 Jul 11;
Forrest G, Plumb C, Ziebland S, Stein A

Objective: To explore father-child communication following the diagnosis of maternal breast cancer, examine disparities in their understandings of the impact of the illness, and identify gaps in their need for support and information.Methods: The design is the qualitative interview study with thematic analysis. The interviews were home-based with fathers and children in Oxfordshire, UK. The participants were 26 fathers whose partners had early breast cancer and 31 of their children aged between 6 and 18 years.Results: Fathers described graphically their reaction to news of their partner's breast cancer and their attempts to provide support for their partners and maintain normal family life for their children. Fathers were keen to reassure and protect children but often said that they lacked sufficient information about breast cancer-especially side effects of treatments. Fathers sometimes did not recognise the extent of their children's distress and some interpreted their children's reactions as 'bad behaviour' or 'rudeness'. Children were often acutely aware of the father's emotional state, and expressed a wish to protect him. Some fathers would have liked an opportunity to talk to a clinician directly about the children but did not want to claim clinical time for themselves or their children.Conclusion: This study suggests that clinicians could improve their care of breast cancer patients by being more family-centred. Fathers routinely need more information and preparation about the likely impact of the illness and its treatment (especially side effects) on the mother, and how children of different ages may react to the emotional strain. Clinicians need to be prepared to offer to talk to teenagers. Copyright (c) 2008 John Wiley & Sons, Ltd.

___
Source: http://www.hubmed.org/display.cgi?uids=18618898
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Abstracting height and weight from medical records, and breast cancer pathologic factors.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 14, 2008 at 4:55 AM
Subject: Abstracting height and weight from medical records, and breast cancer pathologic factors.
To: mesothelioma77@gmail.com

[1]Cancer Causes Control. 2008 Jul 10;
McEligot AJ, Im T, Dillman RO, West JG, Salem R, Haque R, Anton-Culver H

Cancer registries routinely collect data on clinicopathologic factors, but rarely abstract anthropometric variables. We conducted a chart review study, examining the feasibility of abstracting weight, height, alcohol use, and smoking from medical records in women (n = 1,974) diagnosed with invasive breast cancer, and investigated the association between the abstracted variables with clinicopathologic features. Qualitative data were reviewed and categorized. Frequencies of the abstracted data, and demographic and clinicopathologic variables were calculated. Logistic regression models measured the relationship between the outcome variables, tumor size, stage of disease, and estrogen/progesterone (ER/PR) status with the abstracted variables. Data on current alcohol-use/no-use, current-smoker/non-smoker, and height/weight data were obtained on 96%, 97%, and 88-89% of the participants, respectively. The multivariate analysis showed that overweight (>/=25 kg/m(2)) women had significantly larger (>/=2 cm) tumor size compared with normal weight for both women /=50 years at diagnosis (OR = 1.58; 95% CI = 1.19-2.09; p

___
Source: http://www.hubmed.org/display.cgi?uids=18618281
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

http://www.jgvfinance.com/

http://www.jgvfinance.com/Mortgage.html

http://www.jgvfinance.com/Articles.html

http://www.jgvfinance.com/Life_Insurance.html
http://www.jgvfinance.com/Advantages_Of_Whole_Life_Insurance.html
http://www.jgvfinance.com/Accidental_Death_Insurance.html
http://www.jgvfinance.com/Life_Insurance_Companies.html

http://www.jgvfinance.com/Life_Insurance_UK.html

http://www.jgvfinance.com/Over_50s_Life_Insurance.html
http://www.jgvfinance.com/Life_Insurance_Quotes.html
http://www.jgvfinance.com/Whole_Life_Insurance_Or_Term_Life_Insurance.html
http://www.jgvfinance.com/Mortgage_Rates_Predictions.html
http://www.jgvfinance.com/Mortgage_Refinancing.html

http://www.jgvfinance.com/Calculate_A_Mortgage.html
http://www.jgvfinance.com/Online_Mortgage_Calculator_UK.html
http://www.jgvfinance.com/Mortgage_Calculator_UK.html
http://www.jgvfinance.com/How_Much_Can_I_Borrow_For_A_Mortgage.html
http://www.jgvfinance.com/Mortgage_Rates_Predictions_A_Good_Thing_To_Do.html
http://www.jgvfinance.com/Student_Loans.html

http://www.jgvfinance.com/School_Consolidation_Loan.html

http://www.jgvfinance.com/Car_Insurance.html

http://www.jgvfinance.com/Motor_Insurance_Gravesend.html
http://www.jgvfinance.com/Understanding_Automobile_Insurance.html
http://www.jgvfinance.com/LIfe_Insurance_And_What_to_Know.html

http://www.jgvfinance.com/Contact_Us.html
http://www.jgvfinance.com/Life_Insurance_For_Over_50s_and_Seniors_Life_Insurance.html
http://www.jgvfinance.com/Life_Insurance_Quote.html
http://www.jgvfinance.com/Online_Life_Insurance_Quotes.html
http://www.jgvfinance.com/Cheap_Auto_Insurance.html
http://www.jgvfinance.com/Site_Map.html

http://www.jgvfinance.com/Beneficiaries_of_Life_Insurance_Policies.html

Fwd: Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 14, 2008 at 4:55 AM
Subject: Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.
To: mesothelioma77@gmail.com

[1]Breast Cancer Res Treat. 2008 Jul 10;
Auer D, Reimer D, Porto V, Fleischer M, Roessler J, Wiedemair A, Marth C, Müller-Holzner E, Daxenbichler G, Zeimet AG

This study analyzes the relationship between coxsackie-adenovirus receptor (CAR) expression (transmembrane and soluble isoforms) and hormone sensitivity in 95 breast cancers. Furthermore, prognostic significance of the expression of the various CAR isoforms was investigated. In addition, inducibility of CAR expression by estradiol and tamoxifen was assessed in various breast cancer cell lines. Expression of transmembrane CAR (hCAR) highly correlated with estrogen receptivity, but was independent of the expression of progesterone receptor (PR). Furthermore, hCAR expression was significantly higher in tumors with low-grade malignancy. However, no relationship between hCAR expression and tumor size, lymph node status, or survival was revealed. In the hormone receptor-positive breast cancer cell line T47-D expression of hCAR and its soluble isoforms was increased by treatment with estradiol and tamoxifen. In contrast, no induction of either CAR isoform was achieved in receptor-negative cell lines. Furthermore, enhancement of hCAR expression was significantly greater when cells were treated with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) than when treated with estradiol or tamoxifen. Moreover, sensitivity to TSA induction of hCAR was considerably greater in receptor-positive than in receptor-negative cell lines. No additive effect on CAR expression was found when TSA was combined with either estradiol or tamoxifen. In conclusion, the so far undescribed association between estrogen receptivity and the expression of hCAR in breast cancer seems to not only reflect a phenotype of low malignancy, but expression of hCAR may also be directly influenced by ER-specific ligands.

___
Source: http://www.hubmed.org/display.cgi?uids=18618240
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

http://www.jgvfinance.com/

http://www.jgvfinance.com/Mortgage.html

http://www.jgvfinance.com/Articles.html

http://www.jgvfinance.com/Life_Insurance_UK.html

http://www.jgvfinance.com/School_Consolidation_Loan.html

http://www.jgvfinance.com/Car_Insurance.html

http://www.jgvfinance.com/Motor_Insurance_Gravesend.html
http://www.jgvfinance.com/Understanding_Automobile_Insurance.html
http://www.jgvfinance.com/LIfe_Insurance_And_What_to_Know.html

http://www.jgvfinance.com/Beneficiaries_of_Life_Insurance_Policies.html

Fwd: Combined Axillary Reverse Mapping (ARM) Technique for Breast Cancer Patients Requiring Axillary Dissection.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 14, 2008 at 4:55 AM
Subject: Combined Axillary Reverse Mapping (ARM) Technique for Breast Cancer Patients Requiring Axillary Dissection.
To: mesothelioma77@gmail.com

[1]Ann Surg Oncol. 2008 Jul 11;
Nos C, Kaufmann G, Clough KB, Collignon MA, Zerbib E, Cusumano P, Lecuru F

BACKGROUND: The objective of axillary reverse mapping (ARM) is to preserve the main lymphatic chain-with both the nodes and the ducts-in relation to lymphatic arm drainage (LAD) during an axillary dissection (AD). METHODS: From July 2006 to March 2008, 23 patients with stage II or III breast carcinoma requiring an AD underwent an ARM procedure. Identification of the ARM nodes relied on an isotope injection into the web space of the ipsilateral hand. During AD, the radioactive ARM node was localized above the second intercostal brachial nerve, and blue dye was directly injected inside the node to visualize the efferent ducts, constituting the lymphatic ARM chain. The blue and radioactive nodes constituted the ARM sampling, while other nodes were considered part of the AD. RESULTS: Metastatic lymph node involvement was identified in the AD in 20 of 23 patients, with an average of 4.4 (1-11) nodes involved and an average of 10.7 (7-20) lymph nodes removed. The ARM sampling was performed in 21 of 23 patients (91%), with an average of 1.6 ARM nodes removed. In 18 of these 21 patients (86%), the nodes relating to ARM sampling had no metastatic involvement. There were 3 patients (14%) who demonstrated metastatic involvement of the ARM sampling, and all had pN3a (N+ > 9) involvement of the axilla. CONCLUSION: This technique of combined isotopic and blue dye ARM and findings must now be validated. A multicentric study is planned to confirm this data.

___
Source: http://www.hubmed.org/display.cgi?uids=18618185
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

http://www.jgvfinance.com/

http://www.jgvfinance.com/Mortgage.html

http://www.jgvfinance.com/Articles.html

http://www.jgvfinance.com/Life_Insurance_UK.html

http://www.jgvfinance.com/School_Consolidation_Loan.html

http://www.jgvfinance.com/Car_Insurance.html

http://www.jgvfinance.com/Motor_Insurance_Gravesend.html
http://www.jgvfinance.com/Understanding_Automobile_Insurance.html
http://www.jgvfinance.com/LIfe_Insurance_And_What_to_Know.html

http://www.jgvfinance.com/Beneficiaries_of_Life_Insurance_Policies.html

Fwd: Therapy-Related Acute Promyelocytic Leukemia Caused by Hormonal Therapy and Radiation in a Patient with Recurrent Breast Cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 14, 2008 at 4:55 AM
Subject: Therapy-Related Acute Promyelocytic Leukemia Caused by Hormonal Therapy and Radiation in a Patient with Recurrent Breast Cancer.
To: mesothelioma77@gmail.com

[1]Jpn J Clin Oncol. 2008 Jul 10;
Ono M, Watanabe T, Shimizu C, Hiramoto N, Goto Y, Yonemori K, Kouno T, Ando M, Tamura K, Katsumata N, Fujiwara Y

We report a patient with therapy-related acute promyelocytic leukemia (APL) that may have been caused by regional radiation or hormonal therapy after surgery. A 36-year-old Japanese woman developed right breast cancer and underwent breast-conserving surgery and regional radiation to the right breast without adjuvant systemic therapy because she wished to preserve her fertility. Two years later, she developed multiple bone metastases of breast cancer and received hormonal therapy. During the second line hormonal therapy, she developed APL and received induction and consolidation chemotherapy with all-trans retinoic acid (ATRA) and a combination of anthracycline and cytarabine. After she achieved a complete remission (CR) of the APL, her bone metastases of breast cancer progressed. She received weekly paclitaxel treatments and her bone marrow function recovered. However, 9 months later, her APL relapsed; she achieved a second CR after undergoing ATRA therapy again. This patient is thought to be a rare case of secondary leukemia, since the leukemia might have been caused by hormonal therapy and regional radiation without chemotherapy.

___
Source: http://www.hubmed.org/display.cgi?uids=18617535
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: For cancer data worker, the disease has become personal (The Sacramento Bee)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: For cancer data worker, the disease has become personal (The Sacramento Bee)
To: mesothelioma77@gmail.com

For seven years, cancer was a matrix of numbers on Della Blankenship's computer screen. Della Blankenship, who works for the California Cancer Registry, is herself trying to beat a cancer. Della Blankenship, who is being treated for Hodgkin's lymphoma, relaxes with Suki on Thursday in their Land Park apartment. "Every moment that I am alive is the best moment of my life," says the ...

Sat, 19 Jul 2008 07:19:35 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11gui4pb0/*http%3A//www.sacbee.com/101/story/1094046.html
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Lifewatch: Lung cancer development (WECT 6 Wilmington)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Lifewatch: Lung cancer development (WECT 6 Wilmington)
To: mesothelioma77@gmail.com

About 200,000 people are diagnosed with new cases of lung cancer each year. Until now, surgery required long and trying hospital stays. A new development is making recovery faster and less painful.

Wed, 16 Jul 2008 15:28:45 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11ionl980/*http%3A//www.wect.com/global/story.asp?s=8684311
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.
To: mesothelioma77@gmail.com

[1]Int J Med Sci. 2008; 5(4): 197-202
Uhrhammer N, Abdelouahab A, Lafarge L, Feillel V, Dib AB, Bignon YJ

Breast cancer rates and median age of onset differ between Western Europe and North Africa. In Western populations, 5 to 10 % of breast cancer cases can be attributed to major genetic factors such as BRCA1 and BRCA2, while this attribution is not yet well defined among Africans. To help determine the contribution of BRCA1 mutations to breast cancer in a North African population, we analysed genomic DNA from breast cancer cases ascertained in Algiers.Both familial cases (at least three breast cancers in the same familial branch, or two with one bilateral or diagnosed before age 40) and sporadic cases less than 38 years of age were studied. Complete sequencing plus quantitative analysis of the BRCA1 gene was performed. 9.8 % (5/51) of early-onset sporadic and 36.4 % (4/11) of familial cases were found to be associated with BRCA1 mutations. This is in contrast 10.3 % of French HBOC families exhibiting a BRCA1 mutation. One mutation, c.798_799delTT, was observed in two Algerian families and in two families from Tunisia, suggesting a North African founder allele. Algerian non-BRCA1 tumors were of significantly higher grade than French non-BRCA tumors, and the age at diagnosis for Algerian familial cases was much younger than that for French non-BRCA familial cases. In conclusion, we observed a much higher frequency of BRCA1 mutations among young breast cancer patients than observed in Europe, suggesting biological differences and that the inclusion criterea for analysis in Western Europe may not be applicable for the Northern African population.

___
Source: http://www.hubmed.org/display.cgi?uids=18645608
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Sunday, July 27, 2008

Fwd: Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:29 AM
Subject: Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
To: mesothelioma77@gmail.com

[1]J Clin Oncol. 2008 Jul 20; 26(21): 3567-72
Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL

PURPOSE: Pemetrexed in combination with cisplatin is approved for the treatment of pleural mesothelioma and is active in malignant peritoneal mesothelioma (MPeM). Pemetrexed and gemcitabine are synergistic in preclinical models, but the activity of this combination in MPeM is unknown. This clinical study assessed safety and efficacy of pemetrexed plus gemcitabine in chemotherapy-naïve patients with MPeM. PATIENTS AND METHODS: Treatment consisted of gemcitabine 1,250 mg/m(2) on days 1 and 8, and pemetrexed 500 mg/m(2) on day 8, administered immediately before gemcitabine. Treatment was repeated every 21 days for six cycles or until disease progression. All patients received folic acid, vitamin B(12), and dexamethasone supplementation. End points included tumor response, toxicity, time to disease progression (TTPD), and overall survival (OS). Disease control rate (DCR) was also calculated. RESULTS: Twenty patients were enrolled between December 2002 and May 2004. The confirmed response rate was 15% (95% CI, 3.2% to 37.9%), with three patients experiencing a partial response. The DCR was 50% (95% CI, 27.2% to 72.8%). The most common grade 3 to 4 nonhematologic toxicities included fatigue (20%), constipation (10%), vomiting (10%), and dehydration (10%). Hematologic toxicities included grade 3 to 4 neutropenia (60%) and febrile neutropenia (10%). One patient death was attributed to treatment. Median TTPD and OS times were 10.4 months and 26.8 months, respectively. CONCLUSION: The combination of pemetrexed plus gemcitabine was active in patients with MPeM with a notably high incidence of neutropenia. Median TTPD and OS seem promising. This regimen may provide an alternative to standard therapies, especially for patients who cannot tolerate a platinum-based regimen.

___
Source: http://www.hubmed.org/display.cgi?uids=18640937
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Gene test may predict lung cancer survival (Cancerfacts.com)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:29 AM
Subject: Gene test may predict lung cancer survival (Cancerfacts.com)
To: mesothelioma77@gmail.com

ANN ARBOR, Mich. – July 21, 2008 – An analysis involving a specific set of genes can be used to predict which lung cancer patients will have the poorest likelihood of survival, researchers say. The finding could one day lead to a test that would help determine who needs more aggressive treatment.

Tue, 22 Jul 2008 07:38:53 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12dr8df53/*http%3A//www.cancerfacts.com/Home_News.asp?NewsId=2339&CB=14&CancerTypeId=4
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: ORIGINAL ARTICLE: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells (New England Journal of Medicine)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:29 AM
Subject: ORIGINAL ARTICLE: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells (New England Journal of Medicine)
To: mesothelioma77@gmail.com

This study describes a method for capturing circulating tumor cells in patients with non-small-cell lung cancer with the use of antibody tethered to microposts. The isolated cells were of sufficient quantity and purity to genotype and thus could feasibly be used to guide genotype-specific treatment.

Wed, 23 Jul 2008 21:37:13 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12bru2hss/*http%3A//content.nejm.org/cgi/content/short/359/4/366?rss=1&query=current
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Mesothelioma and Personal Injury Lawyers in Jacksonville, Florida

---------- Forwarded message ----------
From: Soapbox on MSN Video - Top Search Results For: mesothelioma <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:12 AM
Subject: Mesothelioma and Personal Injury Lawyers in Jacksonville, Florida
To: mesothelioma77@gmail.com

[1][2]

www.terrellhogan.com – Located in Jacksonville, Florida and serving all of North Florida, the mesothelioma and personal injury lawyers of Terrell Hogan have extensive experience in this type law and has handled thousands of cases on behalf of its clients.

Views: 0

Rating: [3]

Uploaded On: Tue, 22 Jul 2008 20:33:34 -07:00

Tue, 22 Jul 2008 20:33:34 -07:00

* Attachment, application/x-shockwave-flash: [4]Download
___
Source: http://video.msn.com/video.aspx?vid=aafa33de-73b4-41b9-b3d9-d38f68af6a81
--
~
Powered by [8]RssFwd, a service of [9]Blue Sky Factory, Inc

Fwd: Response to Senator Kennedy, Unabridged - Cape Cod Today

---------- Forwarded message ----------
From: car insurance qoutes - Live Search News <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:12 AM
Subject: Response to Senator Kennedy, Unabridged - Cape Cod Today
To: mesothelioma77@gmail.com

F irst, let me say that as a proud liberal, I am and have been an ardent supporter of Senator Kennedy and his initiatives of social and economic justice and one of his more vocal supporters. However, on the issue of siting Cape Wind, I believe he has ...

Wed, 09 Jul 2008 00:59:00 GMT

___
Source: http://www.capecodtoday.com/blogs/index.php/2007/08/09/repsonse_to_senator_kennedy_unabridged?blog=68
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Genomic Characterisation, Chromosomal Assignment and in Vivo Localisation of the Canine High Mobility Group A1 (HMGA1) Gene.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Genomic Characterisation, Chromosomal Assignment and in Vivo Localisation of the Canine High Mobility Group A1 (HMGA1) Gene.
To: mesothelioma77@gmail.com

[1]BMC Genet. 2008 Jul 23; 9(1): 49
Beuing C, Soller JT, Muth M, Wagner S, Dolf G, Schelling C, Richter A, Willenbrock S, Reimann-Berg N, Winkler S, Nolte I, Bullerdiek J, Murua Escobar H

ABSTRACT: BACKGROUND: The high mobility group A1 proteins (HMGA1a/HMGA1b) are highly conserved between mammalian species and widely described as participating in various cellular processes. By inducing DNA conformation changes the HMGA1 proteins indirectly influence the binding of various transcription factors and therefore effect the transcription regulation. In humans chromosomal aberrations affecting the HMGA1 gene locus on HSA 6p21 were described to be the cause for various benign mesenchymal tumours while high titres of HMGA1 proteins were shown to be associated with the neoplastic potential of various types of cancer. Interestingly, the absence of HMGA1 proteins was shown to cause insulin resistance and diabetes in humans and mice. Due to the various similarities in biology and presentation of human and canine cancers the dog has joined the common rodent animal model for therapeutic and preclinical studies. Accordingly, the canine genome was sequenced completely twice but unfortunately this could not solve the structure of canine HMGA1 gene. RESULTS: Herein we report the characterisation of the genomic structure of the canine HMGA1 gene consisting of 7 exons and 6 introns spanning in total 9524bp, the in vivo localisation of the HMGA1 protein to the nucleus, and a chromosomal assignment of the gene by FISH to CFA12q11. Additionally, we evaluated a described canine HMGA1 exon 6 SNP in 55 Dachshunds. CONCLUSIONS: The performed characterisations will make comparative analyses of aberrations affecting the human and canine gene and proteins possible, thereby providing a basis for revealing mechanisms involved in HMGA1 related pathogenesis in both species.

___
Source: http://www.hubmed.org/display.cgi?uids=18651940
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: The effect of dedicated breast surgeons on the short-term outcomes in breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: The effect of dedicated breast surgeons on the short-term outcomes in breast cancer.
To: mesothelioma77@gmail.com

[1]Ann Surg. 2008 Aug; 248(2): 280-5
Zork NM, Komenaka IK, Pennington RE, Bowling MW, Norton LE, Clare SE, Goulet RJ

OBJECTIVE: The impact of breast surgeons on short-term outcomes in breast cancer care was compared at a single institution. SUMMARY BACKGROUND DATA: Many studies have demonstrated a correlation between high procedural volume and lower mortality in technically challenging procedures. Breast cancer treatment has significant impact on patient behavior, psychology, and appearance. Therefore, evaluation of outcomes cannot be limited to only operative mortality and morbidity. We sought to determine the effect of dedicated breast cancer surgeons on short-term outcomes at a single institution. METHODS: Wishard Memorial Hospital is the county hospital affiliated with the Indiana University School of Medicine. A retrospective review was performed of all patients from January 1, 1997, to February 28, 2006. On July 1, 2003, coverage for the Breast Clinic was changed from general surgeons (G) to breast surgeons (B). There were 596 patients included in the study period. RESULTS: There were no significant differences in patient demographics or disease characteristics between the 2 time periods. For early stage (stage I and II) breast cancer, a higher percentage of patients underwent breast conservation in the breast surgeon period than in the general surgeon period (P = 0.04). Lumpectomy margins in breast conserving operations during the G period were more often positive (P = 0.025) or close (

___
Source: http://www.hubmed.org/display.cgi?uids=18650639
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults.
To: mesothelioma77@gmail.com

[1]Cochrane Database Syst Rev. 2008; CD006276
Robb KA, Bennett MI, Johnson MI, Simpson KJ, Oxberry SG

BACKGROUND: Cancer-related pain is complex and multi-dimensional but the mainstay of cancer pain management has predominately used a biomedical approach. There is a need for non-pharmacological and innovative approaches. Transcutaneous Electric Nerve Stimulation (TENS) may have a role for a significant number of patients but the effectiveness of TENS is currently unknown. OBJECTIVES: The aim of this systematic review was to determine the effectiveness of TENS for cancer-related pain in adults. SEARCH STRATEGY: We searched The Cochrane Library, MEDLINE, EMBASE, CINAHL, PsychINFO, AMED and PEDRO databases (11/04/08). SELECTION CRITERIA: Only randomised controlled trials (RCTS) investigating the use of TENS for the management of cancer-related pain in adults were included. DATA COLLECTION AND ANALYSIS: The search strategy identified 37 possible published studies which were divided between two pairs of review authors that decided on study selection. A study eligibility form was used to screen each abstract and where study eligibility could not be determined from the abstract, the full paper was obtained and assessed by one pair of review authors. A standardised data extraction sheet was used to collect information on the studies and the quality of the studies was assessed independently by two review authors using the validated five-point Oxford Quality Scale. Final scores were discussed and agreed between all four review authors. The small sample sizes and differences in patient study populations of the two included studies prevented meta-analysis. MAIN RESULTS: Only two RCTs met the eligibility criteria (64 participants). These studies were heterogenous with respect to study population, sample size, study design, methodological quality, mode of TENS, treatment duration, method of administration and outcome measures used. In one RCT, there were no significant differences between TENS and placebo in women with chronic pain secondary to breast cancer treatment. In the other RCT, there were no significant differences between acupuncture-type TENS and sham in palliative care patients; this study was underpowered. AUTHORS' CONCLUSIONS: The results of this systematic review are inconclusive due to a lack of suitable RCTs. Large multi-centre RCTs are required to assess the value of TENS in the management of cancer-related pain in adults.

___
Source: http://www.hubmed.org/display.cgi?uids=18646140
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Saturday, July 26, 2008

Fwd: Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:29 AM
Subject: Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.
To: mesothelioma77@gmail.com

[1]Eur J Surg Oncol. 2008 Jul 19;
Sioris T, Sihvo E, Salo J, Räsänen J, Knuuttila A

AIMS: Talc pleurodesis using talc slurry via chest tube is a primary option in malignant pleural effusion, since life expectancy is short and surgical decortication is hazardous. Incomplete lung expansion after fluid evacuation, and/or excessive fluid secretion predicts failure of pleurodesis. A mini-invasive alternative was investigated. METHODS: Between March 2004 and September 2005, 51 consecutive patients with malignant pleural effusion, and clinically considered unsuitable for talc pleurodesis, received an indwelling pleural catheter (Denver PleurX). In 47, implantation was done bedside using local anaesthesia. There were 24 men and 27 women, median age 63 (range 36-85) years, receiving 39 right side, 10 left side, and 2 bilateral catheters. There were 19 non-small cell lung cancer cases, 7 mesothelioma, and 25 with other malignancy. Chemotherapy was being given to 18 patients and was not interrupted. RESULTS: Discharge to home was possible in 71% (36 of 71 patients) on the following day. At 2years follow-up in September 2007, one patient was alive. Mean survival was 3months (range 5days to 37+months) for all patients, with best median survivals of 5.5-6months in breast and ovarian cancer. Catheter was removed or replaced in 15% (8 of 51 patients) due to infection, air leak, or blockage. One patient requested decortication for excessive fluid secretion. None required surgery or died due to catheter-related complications. Pleural fusion with subsequent catheter removal was achieved in 21% (11 of 51 patients). CONCLUSIONS: An indwelling pleural catheter is a safe alternative for patients with malignant pleural effusion unsuitable for talc pleurodesis. In some, pleural fusion may be achieved.

___
Source: http://www.hubmed.org/display.cgi?uids=18644696
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Mesothelioma Lawyers in Pennsylvania and New Jersey - Shein Law Center

---------- Forwarded message ----------
From: Soapbox on MSN Video - Top Search Results For: mesothelioma <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:31 PM
Subject: Mesothelioma Lawyers in Pennsylvania and New Jersey - Shein Law Center
To: mesothelioma77@gmail.com

[1][2]

www.sheinlaw.com – At Shein Law Center, our personal injury lawyers have successfully represented many clients in Philadelphia, Pennsylvania and Pennsauken, New Jersey. Shein Law Center specializes in many practice areas, including mesothelioma, dangerous drugs, product liability and more. Please visit www.sheinlaw.com to learn more.

Views: 6

Rating: [3]

Uploaded On: Fri, 25 Jul 2008 23:08:15 -07:00

Fri, 25 Jul 2008 23:08:15 -07:00

* Attachment, application/x-shockwave-flash: [4]Download
___
Source: http://video.msn.com/video.aspx?vid=b0f6cb1f-7fe7-4479-8de1-11b2586c4c01
--
~
Powered by [8]RssFwd, a service of [9]Blue Sky Factory, Inc

Fwd: State's first cancer center set to open in August (WTHR Indianapolis)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: State's first cancer center set to open in August (WTHR Indianapolis)
To: mesothelioma77@gmail.com

Doctors will soon be combating cancer at a new multi-million dollar facility.

Fri, 25 Jul 2008 23:15:48 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11i94uq8q/*http%3A//www.wthr.com/global/story.asp?s=8738382
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Brave cancer victim dies days before wedding (Edinburgh Evening News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Brave cancer victim dies days before wedding (Edinburgh Evening News)
To: mesothelioma77@gmail.com

A YOUNG lung cancer sufferer who vowed to beat the disease to make it to her wedding day has died just days before she was due to be married.

Fri, 25 Jul 2008 09:22:50 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12pfk9ocb/*http%3A//edinburghnews.scotsman.com/latestnews/Brave-cancer-victim-dies-days.4325356.jp
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Asbestos killed former MoD worker (Wiltshire Times)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Asbestos killed former MoD worker (Wiltshire Times)
To: mesothelioma77@gmail.com

A CARPENTER who worked in the Ministry of Defence underground base near Corsham died of lung cancer caused by an industrial disease, a coroner has found.

Fri, 25 Jul 2008 07:08:14 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=13k1s9im3/*http%3A//www.wiltshiretimes.co.uk/news/latestheadlines/display.var.2404815.0.asbestos_killed_former_mod_worker.php
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.
To: mesothelioma77@gmail.com

[1]Clin Breast Cancer. 2008 Jun; 8(3): 287-92
Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N

In this phase III, multinational, randomized trial, the International Breast Cancer Study Group, Breast International Group, and the National Surgical Adjuvant Breast and Bowel Project will attempt to define the effectiveness of cytotoxic therapy for patients with locoregional recurrence of breast cancer. We will evaluate whether chemotherapy prolongs disease-free survival and, secondarily, whether its use improves overall survival and systemic disease-free survival. Quality of life measurements will be monitored during the first 12 months of the study. Women who have had a previous diagnosis of invasive breast cancer treated by mastectomy or breast-conserving surgery and who have undergone complete surgical excision of all macroscopic disease but who subsequently develop isolated local and/or regional ipsilateral invasive recurrence are eligible. Patients are randomized to observation/no adjuvant chemotherapy or to adjuvant chemotherapy; all suitable patients receive radiation, hormonal, and trastuzumab therapy. Radiation therapy is recommended for patients who have not received previous adjuvant radiation therapy but is required for those with microscopically positive margins. The radiation field must encompass the tumor bed plus a surrounding margin to a dose of >/= 40 Gy. Radiation therapy will be administered before, during, or after chemotherapy. All women with estrogen receptor-positive and/or progesterone receptor-positive recurrence must receive hormonal therapy, with the agent and duration to be determined by the patient's investigator. Adjuvant trastuzumab therapy is permitted for those with HER2- positive tumors, provided that intent to treat is declared before randomization. Although multidrug regimens are preferred, the agents, doses, and use of supportive therapy are at the discretion of the investigator.

___
Source: http://www.hubmed.org/display.cgi?uids=18650162
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Air Quality Seems to Have a Target on its Back (Seattlest)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Air Quality Seems to Have a Target on its Back (Seattlest)
To: mesothelioma77@gmail.com

The same day that the Seattle Times tells us that two south Seattle cement plants are pumping 100 pounds of mercury into the air each year, we learned from the P-I that the Bush administration doesn't think asbestos causes cancer . Chronic exposure to tiny levels of mercury in the air can give you the shakes and make you stupid, but it also accumulates in the earth and in water. We're ...

Thu, 24 Jul 2008 18:37:47 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12aemaghe/*http%3A//seattlest.com/2008/07/24/air_quality_seems_to_have_a_target.php
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: A miracle survivor who beat the odds a second time (The Age)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: A miracle survivor who beat the odds a second time (The Age)
To: mesothelioma77@gmail.com

Anita Steiner amazed doctors when she was cleared of a rare cancer - then she fell pregnant, writes Julia Medew.

Fri, 25 Jul 2008 14:18:12 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=13bhj3avm/*http%3A//www.theage.com.au/national/a-miracle-survivor-who-beat-the-odds-a-second-time-20080725-3l30.html
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: [Simple evaluation of numbers of asbestos bodies in bronchoalveolar lavage fluid under light microscopy: analysis of 35 pulmonary nodular lesions]

---------- Forwarded message ----------
From: HubMed - asbestos cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:45 PM
Subject: [Simple evaluation of numbers of asbestos bodies in bronchoalveolar lavage fluid under light microscopy: analysis of 35 pulmonary nodular lesions]
To: mesothelioma77@gmail.com

[1]Rinsho Byori. 2008 Apr; 56(4): 290-6
Kawahara K, Kawasumi H, Nagano T, Sasada S, Okamoto N

More than 1 asbestos body (AB) per ml of bronchoalveolar lavage fluid (BALF) under light microscopy was defined as AB positive (ABP) and suggests an occupational asbestos exposure. We microscopically evaluated the AB number per one ml of BALF, which we defined as the AB concentration (ABC), using bronchoalveolar lavage (BAL) cytocentrifuge slides obtained from 35 patients having pulmonary nodular lesions (20 carcinoma and 15 nonneoplastic disease) and examined the correlation between ABC and clinicopathological data including findings on Helical computed tomography scan (HCTS) and occupational history of asbestos exposure (OHAE). BAL was performed by the standard technique without removing mucous with a gauze filter. AB was microscopically defined as a structure consisting of a core of transparent asbestos surrounded by an iron-protein coat. Twenty of 35 patients were ABP (ABP rate; 57%) and ABC ranged from 0 to 207.98/ml (mean ABC; 11.33/ml). Mean ABC was significantly higher in patients with OHAE (15.04/ml) compared to that in patients without OHAE (3.23/ml). Twenty-two of 35 patients (63%) lacked abnormality on HCTS and among these, 12 patients (55%) were ABP. In 20 pulmonary carcinoma patients, the ABP rate was 85% and ABC ranged from 0 to 31.1/ml (Mean ABC; 2.99/ml). The ABP rate of pulmonary carcinoma patients was 40% (8 patients) and among these, 5 patients (63%) did not show any abnormality on HCTS. In conclusion, our method was simple and useful and should be applied to patients with pulmonary nodular lesions and OHAE, even if there are no abnormalities on HCTS.

___
Source: http://www.hubmed.org/display.cgi?uids=18516963
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Friday, July 25, 2008

Fwd: Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:29 AM
Subject: Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma.
To: mesothelioma77@gmail.com

[1]Ann Thorac Surg. 2008 Aug; 86(2): 391-5
Abdel Rahman AR, Gaafar RM, Baki HA, El Hosieny HM, Aboulkasem F, Farahat EG, Nouh AM, Mansour KA

BACKGROUND: The incidence and pattern of nodal metastases in mesothelioma are not well understood. This study was conducted to evaluate the prevalence and pattern of nodal metastasis in mesothelioma patients. METHODS: The study included 53 patients with mesothelioma. The first 37 patients (group I) underwent combined modality treatment without preoperative mediastinoscopy. The second group included 16 patients (group II) with pretreatment mediastinoscopy. RESULTS: A total of 18 patients had positive lymph nodes, 12 in group I and 6 in group II; of the latter, 4 had positive mediastinoscopy and 2 had positive nodes on final pathology. Postoperatively, a mean of 14 nodes were dissected (range, 5 to 34). In the post-pleuropneumonectomy group, 6 of 14 patients had positive hilar node metastases in addition to positive mediastinal lymph nodes. One patient had positive hilar nodes only. Of the 49 patients operated on, only 7 had no lung invasion by pathologic evaluation, and none had positive hilar nodes. The mechanism of spread of the disease to hilar nodes may be through lung invasion and not due to direct spread from the pleura. This observation raises the possibility that mediastinal nodes should be considered the primary station in patients with mesothelioma, whereas hilar node metastasis necessitated lung invasion first. CONCLUSIONS: The pattern of nodal metastases may be different from that of lung cancer, and multicenter studies are needed to evaluate this observation.

___
Source: http://www.hubmed.org/display.cgi?uids=18640302
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Asbestos asphalt called safe (Calgary Sun)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Asbestos asphalt called safe (Calgary Sun)
To: mesothelioma77@gmail.com

The city has no plans to discontinue the use of recycled asphalt containing asbestos despite concerns raised by both labour leaders and health activists, says Mayor Dave Bronconnier.

Tue, 22 Jul 2008 08:47:49 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=123l6n8t3/*http%3A//calsun.canoe.ca/News/Alberta/2008/07/22/6228961-sun.html
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Asbestos checks target 2 million buildings (The Japan Times)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Asbestos checks target 2 million buildings (The Japan Times)
To: mesothelioma77@gmail.com

The government plans to expand biannual checks on the management of asbestos, which can cause lung cancer, from the current 260,000 buildings to about 2 million, possibly starting next March, to cover almost all private-sector facilities nationwide, official sources said. The Land, Infrastructure, Transport and Tourism Ministry will examine with local officials the 2 million buildings to lessen ...

Tue, 22 Jul 2008 21:03:28 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=11ofoirv7/*http%3A//search.japantimes.co.jp/rss/nn20080723a1.html
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Pa. Department of Health issues statement on BoRit (The Ambler Gazette)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Pa. Department of Health issues statement on BoRit (The Ambler Gazette)
To: mesothelioma77@gmail.com

Pennsylvania Department of Health issued a health consultation document last week stating that current exposures at and near the BoRit asbestos site pose "no apparent public health hazard to the community for cancer effects or no cancer effects."

Wed, 23 Jul 2008 01:11:48 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12s4q0jtl/*http%3A//www.zwire.com/site/news.cfm?newsid=19865835&BRD=1306&PAG=461&dept_id=187829&rfi=6
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Rosetta-based cancer test wins first approval (Globes Online)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Rosetta-based cancer test wins first approval (Globes Online)
To: mesothelioma77@gmail.com

The New York State Department of Health has approved a test for lung cancer based on the company's microRNA technology.

Tue, 22 Jul 2008 17:56:58 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12epgl4ni/*http%3A//www.globes.co.il/serveen/globes/docview.asp?did=1000364358&fid=1725
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Donors give $70,000 to help Assumption BVM School with asbestos removal (Philly.com)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Donors give $70,000 to help Assumption BVM School with asbestos removal (Philly.com)
To: mesothelioma77@gmail.com

Assumption BVM School in West Grove is continuing an asbestos removal project this summer, thanks in part to more than $70,000 in grant money from three organizations during the past school year.

Mon, 21 Jul 2008 21:50:44 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=13rpfucov/*http%3A//www.philly.com/philly/news/20080721_Donors_give__70_000_to_help_Assumption_BVM_School_with_asbestos_removal.html
--
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Major asbestos suit kicks off in Tokyo (The Japan Times)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Major asbestos suit kicks off in Tokyo (The Japan Times)
To: mesothelioma77@gmail.com

What is believed to be the biggest asbestos-related litigation in Japan opened Wednesday at the Tokyo District Court with construction workers and relatives of deceased workers taking the stand to describe years of health problems that could have been prevented. The 178 plaintiffs are demanding a combined ¥6.6 billion in compensation from 46 construction-materials manufacturers and the ...

Wed, 23 Jul 2008 21:04:49 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=11oo9dn3h/*http%3A//search.japantimes.co.jp/rss/nn20080724a2.html
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Wednesday, July 23, 2008

Fwd: Asbestos law costs compo (Herald Sun)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 21, 2008 at 5:48 PM
Subject: Asbestos law costs compo (Herald Sun)
To: mesothelioma77@gmail.com

A LEGAL loophole is costing families of workers killed by asbestos disease up to hundreds of thousands of dollars in compensation

Sun, 20 Jul 2008 14:00:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12nnp9dli/*http%3A//www.news.com.au/heraldsun/story/0,21985,24049138-661,00.html?from=public_rss
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Thursday, July 31, 2008

Tuesday, July 29, 2008

Monday, July 28, 2008

Sunday, July 27, 2008

Saturday, July 26, 2008

Friday, July 25, 2008

Wednesday, July 23, 2008

About Me

More Tips and Info Sites

Mesothelioma Diagnosis, Mesothelioma Lawyer, Malignant Mesothelioma

Blog Archive

Mesothelioma Diagnosis, Mesothelioma Lawyer, www Mesothelioma, Malignant Mesothelioma